Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs CADUET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Not approved for patients <18 years; safety and effectiveness not established.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs CADUET, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and CADUET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and CADUET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.